284 related articles for article (PubMed ID: 18783302)
1. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
Lee S; Gu N; Kim BH; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 May; 34(5):1160-9. PubMed ID: 22503212
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
4. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
Padhi D; Harris R
Clin Pharmacokinet; 2009; 48(5):303-11. PubMed ID: 19566113
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
8. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
9. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
10. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
11. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals.
Padhi D; Salfi M; Harris RZ
Am J Ther; 2007; 14(3):235-40. PubMed ID: 17515696
[TBL] [Abstract][Full Text] [Related]
13. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.
Taylor L; Crockett J; Tayo B; Morrison G
J Clin Pharmacol; 2019 Aug; 59(8):1110-1119. PubMed ID: 30921490
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Harris RZ; Salfi M; Sullivan JT; Padhi D
Clin Pharmacokinet; 2007; 46(6):495-501. PubMed ID: 17518508
[TBL] [Abstract][Full Text] [Related]
17. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).
Padhi D; Harris RZ; Salfi M; Sullivan JT
Clin Pharmacokinet; 2005; 44(5):509-16. PubMed ID: 15871636
[TBL] [Abstract][Full Text] [Related]
18. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.
Padhi D; Langman CB; Fathallah-Shaykh S; Warady BA; Salusky IB; Lee E; Wang C; Posvar E
Pediatr Nephrol; 2012 Oct; 27(10):1953-9. PubMed ID: 22639045
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice.
Arenas MD; de la Fuente V; Delgado P; Gil MT; Gutiérrez P; Ribero J; Rodríguez M; Almadén Y
J Clin Endocrinol Metab; 2013 Apr; 98(4):1718-25. PubMed ID: 23463658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]